Publications by authors named "R Lacroix"
Background: Candidate biomarkers to improve venous thromboembolism (VTE) risk prediction in patients with newly diagnosed multiple myeloma (MM) undergoing anti-myeloma therapy include tissue factor-bearing microvesicles (MV-TF), procoagulant phospholipids (procoag-PPL), and D-dimer.
Objective: We aimed to determine the levels of MV-TF, procoag-PPL, and D-dimer at baseline and during initial anti-myeloma therapy and their association with the risk of VTE.
Methods: This prospective, longitudinal, observational study included 71 patients with newly diagnosed MM who were eligible for anti-myeloma therapy.
Tissue factor (TF) is a transmembrane protein essential for hemostasis. Different forms of active TF circulate in the blood, either as a component of blood cells and extracellular vesicles (EVs) or as a soluble plasma protein. Accumulating experimental and clinical evidence suggests that TF plays an important role in thrombosis.
View Article and Find Full Text PDFSelecting and raising dairy animals that are more likely to reach their potential is a strategy to increase milk production efficiency and overall profitability. However, indicators are necessary for the early identification of animals that are less likely to perform well, allowing for their early culling and ensuring that resources are allocated to those with the highest potential. The objective of this study was to analyze the association between early-life animal health and performance with longevity, production, and profitability.
View Article and Find Full Text PDFArticle Synopsis
- The thrombomodulin (TM) variant c.1611C>A causes the production of a truncated protein (TM536) lacking a cytoplasmic tail and with a shorter transmembrane domain, but little is known about how it is released from cells.
- Research using different endothelial cells showed that TM536 is released through a unique mechanism involving its insertion into the endoplasmic reticulum, where it escapes and enters the typical secretory pathway without being broken down.
- This abnormal release process leads to a soluble TM536 that is less effective at performing its role in activating protein C and is also retained in the early secretory pathway, making it more susceptible to degradation and reducing its presence on the cell surface
Background: Scientific and clinical interest in extracellular vesicles (EVs) is growing. EVs that expose tissue factor (TF) bind factor VII/VIIa and can trigger coagulation. Highly procoagulant TF-exposing EVs are detectable in the circulation in various diseases, such as sepsis, COVID-19, or cancer.
View Article and Find Full Text PDF